123 related articles for article (PubMed ID: 21425312)
1. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties.
Fioravanti J; González I; Medina-Echeverz J; Larrea E; Ardaiz N; González-Aseguinolaza G; Prieto J; Berraondo P
Hepatology; 2011 Jun; 53(6):1864-73. PubMed ID: 21425312
[TBL] [Abstract][Full Text] [Related]
2. The fusion protein of IFN-α and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism.
Fioravanti J; Medina-Echeverz J; Ardaiz N; Gomar C; Parra-Guillén ZP; Prieto J; Berraondo P
J Immunol; 2012 Apr; 188(8):3988-92. PubMed ID: 22422884
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies.
Ji C; Sastry KS; Tiefenthaler G; Cano J; Tang T; Ho ZZ; Teoh D; Bohini S; Chen A; Sankuratri S; Macary PA; Kennedy P; Ma H; Ries S; Klumpp K; Kopetzki E; Bertoletti A
Hepatology; 2012 Dec; 56(6):2027-38. PubMed ID: 22684948
[TBL] [Abstract][Full Text] [Related]
4. Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I.
Berraondo P; Di Scala M; Korolowicz K; Thampi LM; Otano I; Suarez L; Fioravanti J; Aranda F; Ardaiz N; Yang J; Kallakury BV; Tucker RD; Vasquez M; Menne S; Prieto J; González-Aseguinolaza G
J Hepatol; 2015 Aug; 63(2):329-36. PubMed ID: 25772035
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity.
Fernandez-Sendin M; Di Trani CA; Bella A; Vasquez M; Ardaiz N; Gomar C; Arrizabalaga L; Ciordia S; Corrales FJ; Aranda F; Berraondo P
Front Immunol; 2020; 11():620283. PubMed ID: 33708194
[TBL] [Abstract][Full Text] [Related]
6. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.
Echeverria I; Pereboev A; Silva L; Zabaleta A; Riezu-Boj JI; Bes M; Cubero M; Borras-Cuesta F; Lasarte JJ; Esteban JI; Prieto J; Sarobe P
Hepatology; 2011 Jul; 54(1):28-37. PubMed ID: 21452282
[TBL] [Abstract][Full Text] [Related]
7. Balancing the pharmacokinetics and pharmacodynamics of interferon-α2b and human serum albumin fusion protein by proteolytic or reductive cleavage increases its in vivo therapeutic efficacy.
Zhao HL; Xue C; Du JL; Ren M; Xia S; Liu ZM
Mol Pharm; 2012 Mar; 9(3):664-70. PubMed ID: 22224503
[TBL] [Abstract][Full Text] [Related]
8. Target specific hyaluronic acid-interferon alpha conjugate for the treatment of hepatitis C virus infection.
Yang JA; Park K; Jung H; Kim H; Hong SW; Yoon SK; Hahn SK
Biomaterials; 2011 Nov; 32(33):8722-9. PubMed ID: 21872329
[TBL] [Abstract][Full Text] [Related]
9. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.
Ochoa MC; Fioravanti J; Rodriguez I; Hervas-Stubbs S; Azpilikueta A; Mazzolini G; Gúrpide A; Prieto J; Pardo J; Berraondo P; Melero I
Cancer Res; 2013 Jan; 73(1):139-49. PubMed ID: 23149919
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-gold nanoparticle/interferon α complex for targeted treatment of hepatitis C virus infection.
Lee MY; Yang JA; Jung HS; Beack S; Choi JE; Hur W; Koo H; Kim K; Yoon SK; Hahn SK
ACS Nano; 2012 Nov; 6(11):9522-31. PubMed ID: 23092111
[TBL] [Abstract][Full Text] [Related]
11. Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes.
Murao K; Imachi H; Yu X; Cao WM; Nishiuchi T; Chen K; Li J; Ahmed RA; Wong NC; Ishida T
Gut; 2008 May; 57(5):664-71. PubMed ID: 17998316
[TBL] [Abstract][Full Text] [Related]
12. Bifunctional macromolecule activating both OX40 and interferon-α signaling displays potent therapeutic effects in mouse HBV and tumor models.
Mo S; Gu L; Xu W; Liu J; Ding D; Wang Z; Yang J; Kong L; Zhao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107099. PubMed ID: 33091819
[TBL] [Abstract][Full Text] [Related]
13. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
14. Interferon alpha delivery systems for the treatment of hepatitis C.
Thitinan S; McConville JT
Int J Pharm; 2009 Mar; 369(1-2):121-35. PubMed ID: 19103271
[TBL] [Abstract][Full Text] [Related]
15. Encapsulation, pharmacokinetics and tissue distribution of interferon α-2b liposomes after intramuscular injection to rats.
Li H; Yang L; Cheng G; Wei HY; Zeng Q
Arch Pharm Res; 2011 Jun; 34(6):941-8. PubMed ID: 21725815
[TBL] [Abstract][Full Text] [Related]
16. A Semliki forest virus vector engineered to express IFNα induces efficient elimination of established tumors.
Quetglas JI; Fioravanti J; Ardaiz N; Medina-Echeverz J; Baraibar I; Prieto J; Smerdou C; Berraondo P
Gene Ther; 2012 Mar; 19(3):271-8. PubMed ID: 21734727
[TBL] [Abstract][Full Text] [Related]
17. Drug evaluation: Albuferon-alpha--an antiviral interferon-alpha/albumin fusion protein.
Chemmanur AT; Wu GY
Curr Opin Investig Drugs; 2006 Aug; 7(8):750-8. PubMed ID: 16955687
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo.
Pan Q; de Ruiter PE; Metselaar HJ; Kwekkeboom J; de Jonge J; Tilanus HW; Janssen HL; van der Laan LJ
Hepatology; 2012 Jun; 55(6):1673-83. PubMed ID: 22213147
[TBL] [Abstract][Full Text] [Related]
19. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
[TBL] [Abstract][Full Text] [Related]
20. Calcium Phosphate Particles as Pulmonary Delivery System for Interferon-α in Mice.
Morçöl T; Weidner JM; Mehta A; Bell SJD; Block T
AAPS PharmSciTech; 2018 Jan; 19(1):395-412. PubMed ID: 28752471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
